UBS Upgrades Cytokinetics to Buy, Raises Price Target to $115
Benzinga Newsdesk 4 months ago
NewsUpgradesAnalyst RatingsPrice Target
UBS analyst Ashwani Verma upgrades Cytokinetics (NASDAQ:CYTK) from Neutral to Buy and raises the price target from $69 to $115.
UBS analyst Ashwani Verma upgrades Cytokinetics (NASDAQ:CYTK) from Neutral to Buy and raises the price target from $69 to $115.